Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.56 |
| ▸ | NT5E | P21589 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474181 | 0.85 | NT5E (0.67) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL23474154 | 0.85 | NT5E (0.67) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL22036992 | 0.81 | LMNA (0.74) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL2405470 | 0.80 | AHCY (0.57) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL2050570 | 0.80 | AHCY (0.57) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL3036906 | 0.80 | LMNA (0.65) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL21132768 | 0.80 | LMNA (0.65) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL3036901 | 0.80 | LMNA (0.65) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL2047557 | 0.80 | NT5E (0.65) | AHCYNT5ELMNAHIF1ACA5A | |
| SCHEMBL5362967 | 0.80 | NT5E (0.65) | AHCYNT5ELMNAHIF1ACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NUDT1, ITPA, MTAP | AHCY 2188/4885NT5E 97/4885LMNA 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.